Heska Corporation (HSKA)
(Delayed Data from NSDQ)
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[HSKA]
Reports for Purchase
Showing records 41 - 60 ( 64 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Reported Q1 results, reiterating STRONG BUY, $14.50 price target
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
reports record Q4 results, upgrading to STRONG BUY, $14.50 price target
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Beats handily on EPS; new sales strategy getting traction, reiterate SB
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Element POC blood gas and electrolyte analyzer introduced, reiterate SB, $9.50PT
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Industry: Medical - Biomedical and Genetics
As expected, Q2 results sloppy; new sales strategy getting traction, reiterate SB
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Challenged Q1 2013 with numerous moving parts, yet opportunities remain
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Industry: Medical - Biomedical and Genetics
Q1 2013 Veterinary Practice Survey and weather impact analysis
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Industry: Medical - Biomedical and Genetics
Q4 ahead of expectations, transformational acquisition announced, PT to $12.50
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Challenging quarter; placements strong; accretive acquisitions in the pipeline?
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Element DC chemistry analyzer launched, should improve competitive position
Provider: FELTL & COMPANY
Analyst: HAYNOR B